MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: MNKD
- CUSIP: 56400P20
- Previous Close: $0.51
- 50 Day Moving Average: $0.6018
- 200 Day Moving Average: $0.6416
- 52-Week Range: $0.41 - $2.24
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.86
- P/E Growth: 0.1600
- Market Cap: $245.93M
- Outstanding Shares: 478,376,000
- Beta: 3.26
- Return on Equity: -15.95%
- Return on Assets: 46.57%
Companies Related to MannKind:
- Debt-to-Equity Ratio: -0.62%
- Current Ratio: 0.46%
- Quick Ratio: 0.41%
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
Where is MannKind's stock going? Where will MannKind's stock price be in 2017?
5 analysts have issued 12-month price objectives for MannKind's stock. Their forecasts range from $0.10 to $0.70. On average, they anticipate MannKind's stock price to reach $0.32 in the next year.
When will MannKind announce their earnings?
MannKind is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns MannKind stock?
MannKind's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (1.06%), Harel Insurance Investments & Financial Services Ltd. (0.62%), GSA Capital Partners LLP (0.52%) and State Board of Administration of Florida Retirement System (0.03%). Company insiders that own MannKind stock include Hakan Edstrom, Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya.
Who bought MannKind stock? Who is buying MannKind stock?
MannKind's stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP and State Street Corp. Company insiders that have bought MannKind stock in the last two years include Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya.
How do I buy MannKind stock?
Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of MannKind stock cost?
One share of MannKind stock can currently be purchased for approximately $0.51.